CareDx, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 04, 2022 at 05:20 pm EDT
Share
CareDx, Inc reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 80.63 million compared to USD 74.19 million a year ago. Net loss was USD 21.7 million compared to USD 1.93 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.41 compared to USD 0.04 a year ago.
For the six months, revenue was USD 160.05 million compared to USD 141.59 million a year ago. Net loss was USD 41.35 million compared to USD 2.61 million a year ago. Basic loss per share from continuing operations was USD 0.78 compared to USD 0.05 a year ago. Diluted loss per share from continuing operations was USD 0.78 compared to USD 0.05 a year ago.
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.